Spectral Medical Inc.

135 The West Mall, Unit 2
Toronto
Ontario
M9C 1C2
Canada

Tel: 416-626-3233 or 888-426-4264
Fax: 416-626-7383

Website: http://www.spectraldx.com/

Email: info@spectraldx.com

Show jobs for this employer

About Spectral Medical Inc.

Sepsis affects approximately 1,000,000 patients in the U.S. alone each year and millions worldwide. The ability to rapidly and accurately diagnose and treat this deadly disease remains one of the biggest challenges faced by healthcare professionals today. Using a unique and innovative theranostics approach, Spectral Medical is committed to decreasing the unacceptably high mortality rates caused by sepsis. By combining complementary diagnostics and therapeutics, or theranostics, Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.
LEADERSHIP:
CEO: Paul Walker
CFO: Tony Businskas
PRODUCTS:
All Products

29 articles with Spectral Medical Inc.

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. ( “ Dialco ” ), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market, today announced that its wholly owned subsidiary, Dialco Medical Inc. ( “ Dialco ” ) received its Med

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market, today announced that a paper reporting on the deployment and use of its SAMI unit during the COVID-19 pandemic has been published in the Journal of Blood Purification.

  • Dialco’s DIMI receives FDA 510(k) clearance for use in hospital and clinical settings – a significant step in the full regulatory development of DIMI

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical In. (“Dialco”) , are pleased to announce the following sponsored symposiums at the virtual 38 th Vicenza Course on AKI and CRRT from Monday, November 2nd, 2020 to Friday, November 6th, 2020: Meet the Expert: Is Endotoxemia Relevant in COVID-19? Moderator: Kianoush Kashani, Guest Speakers: Sandeep Mallipattu, and David Yamane Novemb

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , announced today that Dr. Paul Walker, Spectral’s Chief Executive Officer and Chris Seto, Spectral’s Chief Operating and Chief Financial Officer will be presenting virtually at the H.C. Wainwright & Co.  22 nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 5:00 p.m. ET. About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its un

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , today announced that its wholly owned subsidiary, Dialco Medical Inc. ( “Dialco” ) has been granted 510(k) clearance by the United States Food and Drug Administration ( “FDA" )  for DIMI to tr

  • Spectral Medical Inc., (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2020. Financial Review Revenue for the three-months ended June 30, 2020 was $517,000 compared to $1,041,000 for the same three-month period last year. For the six-months ended June 30, 2020, revenue was $1,148,000 compared to $1,588,000 in the

  • Protocol Amendment allows for increase in TIGRIS sites to 15 while potentially accelerating patient enrolling and offsetting any COVID-19 pandemic-related delays

  • Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, provided a corporate update on its Tigris trial, COVID-19 initiatives, EAA launch, and Dialco regulatory activities.

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that, at the annual general and special meeting (the “ Meeting ”) of shareholders of the Company (“ Shareholders ”) that was held yesterday, all five nominees for the board of directors of the Company were elected, the voting results of which are as follows: Director Votes

  • Spectral Medical Inc., (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2020. Financial Review Revenue for the three-months ended March 31, 2020 was $631,000 compared to $547,000 for the same three-month period last year, representing an increase of $84,000 or 15%. Operating costs for the quarter ended March 31, 2020

  • Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, released an update on the impact of COVID-19 on the Company’s business, the measures it has put in place, accordingly, and its long-term strategy.

  • Spectral Medical Inc. announced that Health Canada has issued an Interim Order expanding the already approved indications for use of Spectral’s Toraymyxin™ hemoperfusion cartridge specifically for patients with COVID-19.

  • Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce that the United States Federal Food and Drug Agency (“FDA”) has approved a supplemental Investigational Device Exemption (“IDE”) for the use of Spectral’s PMX cartridge (“PMX”) in the treatment of patients with COVID-19.

  • Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to provide an update on the commercialization activities at Dialco Medical Inc., a wholly-owned subsidiary of Spectral, with respect to its SAMI device for CRRT.

  • Spectral Medical Inc., today announced its financial results for the fourth quarter and for the year ended December 31, 2019. Financial Review Revenue for the three months ended December 31, 2019 was $746,000 compared to $1,864,000 for the same three-month period last year. Revenue for the year ended December 31, 2019 was $2,868,000 compared

  • Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Spectral Medical Inc. (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a distribution agreement for TORAYMYXIN™ PMX-20R (PMX), a hemoperfusion filter, and the Endotoxin Activity Assay™ (EAA), an on-market companion diagnostic tool that aids in the risk assessment of ICU patients for progression to severe sepsis

  • Spectral Medical Inc.,, a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, announced its unaudited financial results for the third quarter ended September 30, 2019.

  • Spectral Medical Inc. commenced trading on Toronto Stock Exchange on June 6, 1994.